{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:19:37Z","timestamp":1774084777418,"version":"3.50.1"},"reference-count":87,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100001411","name":"ICMR","doi-asserted-by":"publisher","award":["5\/13\/57\/2015-NCD-III"],"award-info":[{"award-number":["5\/13\/57\/2015-NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Quinacrine (QC) is a tricyclic compound and a derivative of 9-aminoacridine. It has been widely used\nto treat malaria and other parasitic diseases since the last century. Interestingly, studies have revealed that it also\ndisplays anti-cancer activities. Here, we have discussed the anti-cancer mechanism of QC along with its potentiality\nto specifically target cancer stem cells. The anti-cancer action of this drug includes DNA intercalation,\ninhibition of DNA repair mechanism, prevention of cellular growth, cell cycle arrest, inhibition of DNA and\nRNA polymerase activity, induction of autophagy, promotion of apoptosis, deregulation of cell signaling in\ncancer cells and cancer stem cells, inhibition of metastasis and angiogenesis. In addition, we have also emphasized\non the synergistic effect of this drug with other potent chemotherapeutic agents and mentioned its different\napplications in anti-cancer therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520620666200721123046","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T04:20:25Z","timestamp":1595478025000},"page":"416-427","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-Cancer Stem Cells Potentiality of an Anti-Malarial Agent Quinacrine: An Old Wine in a New Bottle"],"prefix":"10.2174","volume":"21","author":[{"given":"Biswajit","family":"Das","sequence":"first","affiliation":[{"name":"Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha 751024,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-1030","authenticated-orcid":true,"given":"Chanakya N.","family":"Kundu","sequence":"additional","affiliation":[{"name":"Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha 751024,India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","author":"Ehsanian R.","unstructured":"Ehsanian R.; Van Waes C.; Feller S.M.; Beyond DNA binding - a\nreview of the potential mechanisms mediating quinacrine\u2019s therapeutic\nactivities in parasitic infections, inflammation, and cancers.\nCell Commun. Signal., 2011, 9(1), 13.","DOI":"10.1186\/1478-811X-9-13"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2217\/fon-2017-0728","volume":"14","author":"Yan H.","year":"2018","unstructured":"Yan H.; Bian A.; Gao X.; Li H.; Chen Z.; Liu X.; Novel applications for an established antimalarial drug: Tumoricidal activity of quinacrine. Future Oncol 2018,14(15),1511-1520","journal-title":"Future Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"17448","DOI":"10.1073\/pnas.0508888102","volume":"102","author":"Gurova K.V.","year":"2005","unstructured":"Gurova K.V.; Hill J.E.; Guo C.; Prokvolit A.; Burdelya L.G.; Samoylova E.; Khodyakova A.V.; Ganapathi R.; Ganapathi M.; Tararova N.D.; Bosykh D.; Lvovskiy D.; Webb T.R.; Stark G.R.; Gudkov A.V.; Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005,102(48),17448-17453","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/bjc.1997.272","volume":"75","author":"de Souza P.L.","year":"1997","unstructured":"de Souza P.L.; Castillo M.; Myers C.E.; Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br J Cancer 1997,75(11),1593-1600","journal-title":"Br J Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4067\/S0716-97602002000300008","volume":"35","author":"Illanes J.","year":"2002","unstructured":"Illanes J.; Dabancens A.; Acu&#xF1;a O.; Fuenzalida M.; Guerrero A.; Lopez C.; Lemus D.; Effects of betamethasone, sulindac and quinacrine drugs on the inflammatory neoangiogenesis response induced by polyurethane sponge implanted in mouse. Biol Res 2002,35(3-4),339-345","journal-title":"Biol Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/1078-0432.CCR-17-1716","volume":"24","author":"Zhu S.","year":"2018","unstructured":"Zhu S.; Chen Z.; Wang L.; Peng D.; Belkhiri A.; Lockhart A.C.; El-Rifai W.; A combination of SAHA and quinacrine is effective in inducing cancer cell death in upper gastrointestinal cancers. Clin Cancer Res 2018,24(8),1905-1916","journal-title":"Clin Cancer Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.dnarep.2016.05.034","volume":"45","author":"Siddharth S.","year":"2016","unstructured":"Siddharth S.; Nayak D.; Nayak A.; Das S.; Kundu C.N.; ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli. DNA Repair (Amst) 2016,45,44-55","journal-title":"DNA Repair (Amst)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10495-017-1400-4","volume":"22","author":"Das S.","year":"2017","unstructured":"Das S.; Tripathi N.; Siddharth S.; Nayak A.; Nayak D.; Sethy C.; Bharatam P.V.; Kundu C.N.; Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Apoptosis 2017,22(10),1205-1224","journal-title":"Apoptosis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1158\/1078-0432.CCR-15-2792","volume":"22","author":"Abdulghani J.","year":"2016","unstructured":"Abdulghani J.; Gokare P.; Gallant J.N.; Dicker D.; Whitcomb T.; Cooper T.; Liao J.; Derr J.; Liu J.; Goldenberg D.; Finnberg N.K.; El-Deiry W.S.; Sorafenib and quinacrine target anti-apoptotic protein MCL1: A poor prognostic marker in Anaplastic Thyroid Cancer (ATC). Clin Cancer Res 2016,22(24),6192-6203","journal-title":"Clin Cancer Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1166\/jbn.2015.2079","volume":"11","author":"Sun M.G.","year":"2015","unstructured":"Sun M.G.; Shi J.F.; Li X.Y.; Zhao Y.; Ju R.J.; Mu L.M.; Yan Y.; Li X.T.; Zeng F.; Lu W.L.; Targeting epirubicin plus quinacrine liposomes modified with DSPE-PEG2000-C (RGDfK) conjugate for eliminating invasive breast cancer. J Biomed Nanotechnol 2015,11(8),1339-1353","journal-title":"J Biomed Nanotechnol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3109\/1061186X.2014.979829","volume":"23","author":"Li X.T.","year":"2015","unstructured":"Li X.T.; Zhou Z.Y.; Jiang Y.; He M.L.; Jia L.Q.; Zhao L.; Cheng L.; Jia T.Z.; PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer. J Drug Target 2015,23(3),232-243","journal-title":"J Drug Target"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/neuonc\/not119","volume":"15","author":"Lobo M.R.","year":"2013","unstructured":"Lobo M.R.; Green S.C.; Schabel M.C.; Gillespie G.Y.; Woltjer R.L.; Pike M.M.; Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma. Neuro-oncol 2013,15(12),1673-1683","journal-title":"Neuro-oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000313525","volume":"56","author":"Wang Y.","year":"2010","unstructured":"Wang Y.; Bi Q.; Dong L.; Li X.; Ge X.; Zhang X.; Fu J.; Wu D.; Li S.; Quinacrine enhances cisplatin-induced cytotoxicity in four cancer cell lines. Chemotherapy 2010,56(2),127-134","journal-title":"Chemotherapy"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4161\/cbt.12.3.17034","volume":"12","author":"Gallant J.N.","year":"2011","unstructured":"Gallant J.N.; Allen J.E.; Smith C.D.; Dicker D.T.; Wang W.; Dolloff N.G.; Navaraj A.; El-Deiry W.S.; Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther 2011,12(3),239-251","journal-title":"Cancer Biol Ther"},{"key":"ref=15","first-page":"969","volume":"49","author":"Reyes S.","year":"2001","unstructured":"Reyes S.; Herrera L.A.; Ostrosky P.; Sotelo J.; Quinacrine enhances carmustine therapy of experimental rat glioma. Neurosurgery 2001,49(4),969-973","journal-title":"Neurosurgery"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"19162","DOI":"10.1074\/jbc.M109.091645","volume":"285","author":"Jani T.S.","year":"2010","unstructured":"Jani T.S.; DeVecchio J.; Mazumdar T.; Agyeman A.; Houghton J.A.; Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) or oxaliplatin. J Biol Chem 2010,285(25),19162-19172","journal-title":"J Biol Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1472-8206.2008.00613.x","volume":"22","author":"Liang G.W.","year":"2008","unstructured":"Liang G.W.; Lu W.L.; Wu J.W.; Zhao J.H.; Hong H.Y.; Long C.; Li T.; Zhang Y.T.; Zhang H.; Wang J.C.; Zhang X.; Zhang Q.; Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundam Clin Pharmacol 2008,22(4),429-437","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bcp.2016.01.017","volume":"105","author":"Preet R.","year":"2016","unstructured":"Preet R.; Siddharth S.; Satapathy S.R.; Das S.; Nayak A.; Das D.; Wyatt M.D.; Kundu C.N.; Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol 2016,105,23-33","journal-title":"Biochem Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.biomaterials.2011.09.055","volume":"33","author":"Zhang L.","year":"2012","unstructured":"Zhang L.; Yao H.J.; Yu Y.; Zhang Y.; Li R.J.; Ju R.J.; Wang X.X.; Sun M.G.; Shi J.F.; Lu W.L.; Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012,33(2),565-582","journal-title":"Biomaterials"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4161\/cbt.12.3.17033","volume":"12","author":"Wang W.","year":"2011","unstructured":"Wang W.; Gallant J.N.; Katz S.I.; Dolloff N.G.; Smith C.D.; Abdulghani J.; Allen J.E.; Dicker D.T.; Hong B.; Navaraj A.; El-Deiry W.S.; Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther 2011,12(3),229-238","journal-title":"Cancer Biol Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13046-019-1212-1","volume":"38","author":"Matteoni S.","year":"2019","unstructured":"Matteoni S.; Abbruzzese C.; Matarrese P.; De Luca G.; Mileo A.M.; Miccadei S.; Schenone S.; Musumeci F.; Haas T.L.; Sette G.; Carapella C.M.; Amato R.; Perrotti N.; Signore M.; Paggi M.G.; The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells. J Exp Clin Cancer Res 2019,38(1),202","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.leukres.2017.10.012","volume":"63","author":"Eriksson A.","year":"2017","unstructured":"Eriksson A.; Chantzi E.; Frykn&#xE4;s M.; Gullbo J.; Nygren P.; Gustafsson M.; H&#xF6;glund M.; Larsson R.; Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects. Leuk Res 2017,63,41-46","journal-title":"Leuk Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.surg.2004.01.008","volume":"136","author":"Sotelo J.","year":"2004","unstructured":"Sotelo J.; Guevara P.; Pineda B.; Diaz C.; Interstitial quinacrine activates a distinctive immune response effective for tumor immunotherapy. Surgery 2004,136(3),700-707","journal-title":"Surgery"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.20517\/2394-4722.2019.15","volume":"5","author":"Robinson N.J.","year":"2019","unstructured":"Robinson N.J.; Taylor D.J.; Schiemann W.P.; Stem cells, immortality, and the evolution of metastatic properties in breast cancer: Telomere maintenance mechanisms and metastatic evolution. J Cancer Metastasis Treat 2019,5,39","journal-title":"J Cancer Metastasis Treat"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1021\/acs.molpharmaceut.5b00461","volume":"12","author":"Satapathy S.R.","year":"2015","unstructured":"Satapathy S.R.; Siddharth S.; Das D.; Nayak A.; Kundu C.N.; Enhancement of cytotoxicity and inhibition of angiogenesis in oral cancer stem cells by a hybrid nanoparticle of bioactive quinacrine and silver: Implication of base excision repair cascade. Mol Pharm 2015,12(11),4011-4025","journal-title":"Mol Pharm"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nano.2018.01.007","volume":"14","author":"Satapathy S.R.","year":"2018","unstructured":"Satapathy S.R.; Nayak A.; Siddharth S.; Das S.; Nayak D.; Kundu C.N.; Metallic gold and bioactive quinacrine hybrid nanoparticles inhibit oral cancer stem cell and angiogenesis by deregulating inflammatory cytokines in p53 dependent manner. Nanomedicine (Lond) 2018,14(3),883-896","journal-title":"Nanomedicine (Lond)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.taap.2017.07.008","volume":"330","author":"Nayak A.","year":"2017","unstructured":"Nayak A.; Siddharth S.; Das S.; Nayak D.; Sethy C.; Kundu C.N.; Nanoquinacrine caused apoptosis in oral cancer stem cells by disrupting the interaction between GLI1 and &#x3B2; catenin through activation of GSK3&#x3B2;. Toxicol Appl Pharmacol 2017,330,53-64","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1021\/acs.molpharmaceut.9b00242","volume":"16","author":"Hembram K.C.","year":"2019","unstructured":"Hembram K.C.; Chatterjee S.; Sethy C.; Nayak D.; Pradhan R.; Molla S.; Bindhani B.K.; Kundu C.N.; Comparative and mechanistic study on the anticancer activity of quinacrine-based silver and gold hybrid nanoparticles in head and neck cancer. Mol Pharm 2019,16(7),3011-3023","journal-title":"Mol Pharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13402-018-0417-1","volume":"42","author":"Nayak A.","year":"2019","unstructured":"Nayak A.; Das S.; Nayak D.; Sethy C.; Narayan S.; Kundu C.N.; Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation. Cell Oncol (Dordr) 2019,42(2),157-171","journal-title":"Cell Oncol (Dordr)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/onc.2008.460","volume":"28","author":"Guo C.","year":"2009","unstructured":"Guo C.; Gasparian A.V.; Zhuang Z.; Bosykh D.A.; Komar A.A.; Gudkov A.V.; Gurova K.V.; 9-Aminoacridine-based anticancer drugs target the PI3K\/AKT\/mTOR, NF-kappaB and p53 pathways. Oncogene 2009,28(8),1151-1161","journal-title":"Oncogene"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1097-2765(02)00477-X","volume":"9","author":"Zhong H.","year":"2002","unstructured":"Zhong H.; May M.J.; Jimi E.; Ghosh S.; The phosphorylation status of nuclear NF-&#x3BA;B determines its association with CBP\/p300 or HDAC-1. Mol Cell 2002,9(3),625-636","journal-title":"Mol Cell"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1038\/sj.onc.1209943","volume":"25","author":"Hayden M.S.","year":"2006","unstructured":"Hayden M.S.; West A.P.; Ghosh S.; NF-kappaB and the immune response. Oncogene 2006,25(51),6758-6780","journal-title":"Oncogene"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/35410","volume":"391","author":"Magnaghi-Jaulin L.","year":"1998","unstructured":"Magnaghi-Jaulin L.; Groisman R.; Naguibneva I.; Robin P.; Lorain S.; Le Villain J.P.; Troalen F.; Trouche D.; Harel-Bellan A.; Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 1998,391(6667),601-605","journal-title":"Nature"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-14-0013","volume":"13","author":"Dermawan J.K.","year":"2014","unstructured":"Dermawan J.K.; Gurova K.; Pink J.; Dowlati A.; De S.; Narla G.; Sharma N.; Stark G.R.; Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-&#x3BA;B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 2014,13(9),2203-2214","journal-title":"Mol Cancer Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s00216-004-2797-5","volume":"380","author":"Aslanoglu M.","year":"2004","unstructured":"Aslanoglu M.; Ayne G.; Voltammetric studies of the interaction of quinacrine with DNA. Anal Bioanal Chem 2004,380(4),658-663","journal-title":"Anal Bioanal Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2217\/fon.09.127","volume":"5","author":"Gurova K.","year":"2009","unstructured":"Gurova K.; New hopes from old drugs: Revisiting DNA-binding small molecules as anticancer agents. Future Oncol 2009,5(10),1685-1704","journal-title":"Future Oncol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2174\/1381612013397131","volume":"7","author":"Demeunynck M.","year":"2001","unstructured":"Demeunynck M.; Charmantray F.; Martelli A.; Interest of acridine derivatives in the anticancer chemotherapy. Curr Pharm Des 2001,7(17),1703-1724","journal-title":"Curr Pharm Des"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/0277-5379(89)90337-4","volume":"25","author":"Finlay G.J.","year":"1989","unstructured":"Finlay G.J.; Wilson W.R.; Baguley B.C.; Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. Eur J Cancer Clin Oncol 1989,25(12),1695-1701","journal-title":"Eur J Cancer Clin Oncol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ijc.26158","volume":"130","author":"Preet R.","year":"2012","unstructured":"Preet R.; Mohapatra P.; Mohanty S.; Sahu S.K.; Choudhuri T.; Wyatt M.D.; Kundu C.N.; Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer 2012,130(7),1660-1670","journal-title":"Int J Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.31]","volume":"5","author":"Eriksson A.","year":"2015","unstructured":"Eriksson A.; &#xD6;sterroos A.; Hassan S.; Gullbo J.; Rickardson L.; Jarvius M.; Nygren P.; Frykn&#xE4;s M.; H&#xF6;glund M.; Larsson R.; Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J 2015,5(4)","journal-title":"Blood Cancer J"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.curtheres.2012.02.003","volume":"73","author":"Wu X.","year":"2012","unstructured":"Wu X.; Wang Y.; Wang H.; Wang Q.; Wang L.; Miao J.; Cui F.; Wang J.; Quinacrine inhibits cell growth and induces apoptosis\nin human gastric cancer cell line SGC-7901 Curr Ther Res Clin\nExp 2012,73(1-2),52-64","journal-title":"Curr Ther Res Clin\nExp"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002530","volume":"3","author":"Gasparian A.V.","year":"2011","unstructured":"Gasparian A.V.; Burkhart C.A.; Purmal A.A.; Brodsky L.; Pal M.; Saranadasa M.; Bosykh D.A.; Commane M.; Guryanova O.A.; Pal S.; Safina A.; Sviridov S.; Koman I.E.; Veith J.; Komar A.A.; Gudkov A.V.; Gurova K.V.; Curaxins: Anticancer compounds that simultaneously suppress NF-&#x3BA;B and activate p53 by targeting FACT. Sci Transl Med 2011,3(95)","journal-title":"Sci Transl Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1126\/science.1085703","volume":"301","author":"Belotserkovskaya R.","year":"2003","unstructured":"Belotserkovskaya R.; Oh S.; Bondarenko V.A.; Orphanides G.; Studitsky V.M.; Reinberg D.; FACT facilitates transcription-dependent nucleosome alteration. Science 2003,301(5636),1090-1093","journal-title":"Science"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.celrep.2013.06.013","volume":"4","author":"Garcia H.","year":"2013","unstructured":"Garcia H.; Miecznikowski J.C.; Safina A.; Commane M.; Ruusulehto A.; Kilpinen S.; Leach R.W.; Attwood K.; Li Y.; Degan S.; Omilian A.R.; Guryanova O.; Papantonopoulou O.; Wang J.; Buck M.; Liu S.; Morrison C.; Gurova K.V.; Facilitates chromatin transcription complex is an &#x201C;accelerator&#x201D; of tumor transformation and potential marker and target of aggressive cancers. Cell Rep 2013,4(1),159-173","journal-title":"Cell Rep"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.021","author":"Oien D.B.","unstructured":"Oien D.B.; Pathoulas C.L.; Ray U.; Thirusangu P.; Kalogera E.; Shridhar V.;  Repurposing quinacrine for treatment-refractory cancer\nSemin Cancer Biol 2019 [In Press]","journal-title":"Repurposing quinacrine for treatment-refractory cancer\nSemin Cancer Biol 2019 [In Press]"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1038\/s41598-018-20531-w","volume":"8","author":"Jung D.","year":"2018","unstructured":"Jung D.; Khurana A.; Roy D.; Kalogera E.; Bakkum-Gamez J.; Chien J.; Shridhar V.; Quinacrine upregulates p21\/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. Sci Rep 2018,8(1),2487","journal-title":"Sci Rep"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","volume":"13","author":"Sherr C.J.","year":"1999","unstructured":"Sherr C.J.; Roberts J.M.; CDK inhibitors: Positive and negative\nregulators of G1-phase progression. Genes Dev 1999,13(12),1501-1512","journal-title":"Genes Dev"},{"key":"ref=48","first-page":"522","volume":"17","author":"Yang S.","year":"2018","unstructured":"Yang S.; Sheng L.; Xu K.; Wang Y.; Zhu H.; Zhang P.; Mu Q.; Ouyang G.; Anticancer effect of quinacrine on diffuse large B cell lymphoma via inhibition of MSI2 NUMB signaling pathway. Mol Med Rep 2018,17(1),522-530","journal-title":"Mol Med Rep"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.procbio.2019.03.007","volume":"81","author":"Sabzichi M.","year":"2019","unstructured":"Sabzichi M.; Ramezani M.; Mohammadian J.; Ghorbani M.; Mardomi A.; Najafipour F.; Mehdizadeh A.; The synergistic impact\nof quinacrine on cell cycle and anti-invasiveness behaviors of\ndoxorubicin in MDA-MB-231 breast cancer cells Process Biochem 2019,81(1),175-181","journal-title":"Process Biochem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"702","DOI":"10.4172\/pharmaceutical-sciences.1000410","volume":"80","author":"Kawade V.S.","year":"2018","unstructured":"Kawade V.S.; Satpute P.S.; Dhulap S.A.; Gurjar S.; Therapeutic\npotential of PI3K\/Akt\/mTOR signalling pathway: Effective combination\ntherapy for cancer. Indian J Pharm Sci 2018,80(4),702-708","journal-title":"Indian J Pharm Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccr.2012.04.027","volume":"21","author":"Jackson J.G.","year":"2012","unstructured":"Jackson J.G.; Pant V.; Li Q.; Chang L.L.; Quint&#xE1;s-Cardama A.; Garza D.; Tavana O.; Yang P.; Manshouri T.; Li Y.; El-Naggar A.K.; Lozano G.; p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012,21(6),793-806","journal-title":"Cancer Cell"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/1541-7786.MCR-17-0511","volume":"16","author":"Park S.","year":"2018","unstructured":"Park S.; Oh A.Y.; Cho J.H.; Yoon M.H.; Woo T.G.; Kang S.M.; Lee H.Y.; Jung Y.J.; Park B.J.; Therapeutic effect of quinacrine, an antiprotozoan drug, by selective suppression of p-CHK1\/2 in p53-negative malignant cancers. Mol Cancer Res 2018,16(6),935-946","journal-title":"Mol Cancer Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1056\/NEJMra1205406","volume":"368","author":"Choi A.M.","year":"2013","unstructured":"Choi A.M.; Ryter S.W.; Levine B.; Autophagy in human health and disease. N Engl J Med 2013,368(7),651-662","journal-title":"N Engl J Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41418-019-0292-y","volume":"26","author":"Nazio F.","year":"2019","unstructured":"Nazio F.; Bordi M.; Cianfanelli V.; Locatelli F.; Cecconi F.; Autophagy and cancer stem cells: Molecular mechanisms and therapeutic applications. Cell Death Differ 2019,26(4),690-702","journal-title":"Cell Death Differ"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/cr.2011.152","volume":"22","author":"Wirawan E.","year":"2012","unstructured":"Wirawan E.; Vanden Berghe T.; Lippens S.; Agostinis P.; Vandenabeele P.;  Autophagy: For better or for worse. Cell Res 2012,22(1),43-61","journal-title":"Cell Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/1535-7163.MCT-06-0478","volume":"5","author":"Kuo P.L.","year":"2006","unstructured":"Kuo P.L.; Hsu Y.L.; Cho C.Y.; Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT\/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 2006,5(12),3209-3221","journal-title":"Mol Cancer Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2008.06.004","volume":"14","author":"Turcotte S.","year":"2008","unstructured":"Turcotte S.; Chan D.A.; Sutphin P.D.; Hay M.P.; Denny W.A.; Giaccia A.J.; A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 2008,14(1),90-102","journal-title":"Cancer Cell"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1128\/AAC.47.12.3708-3712.2003","volume":"47","author":"Auparakkitanon S.","year":"2003","unstructured":"Auparakkitanon S.; Noonpakdee W.; Ralph R.K.; Denny W.A.; Wilairat P.; Antimalarial 9-anilinoacridine compounds directed at hematin. Antimicrob Agents Chemother 2003,47(12),3708-3712","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3727\/096504012X13473664562628","volume":"20","author":"Mohapatra P.","year":"2012","unstructured":"Mohapatra P.; Preet R.; Das D.; Satapathy S.R.; Choudhuri T.; Wyatt M.D.; Kundu C.N.; Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53- and p21-dependent mechanism. Oncol Res 2012,20(2-3),81-91","journal-title":"Oncol Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"893","DOI":"10.4161\/cbt.4.8.2134","volume":"4","author":"Wang W.","year":"2005","unstructured":"Wang W.; Ho W.C.; Dicker D.T.; MacKinnon C.; Winkler J.D.; Marmorstein R.; El-Deiry W.S.; Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 2005,4(8),893-898","journal-title":"Cancer Biol Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.taap.2015.02.005","volume":"284","author":"Changchien J.J.","year":"2015","unstructured":"Changchien J.J.; Chen Y.J.; Huang C.H.; Cheng T.L.; Lin S.R.; Chang L.S.; Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK\/c-Jun-mediated BCL2L1 expression. Toxicol Appl Pharmacol 2015,284(1),33-41","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.taap.2017.08.019","volume":"334","author":"Huang C.H.","year":"2017","unstructured":"Huang C.H.; Lee Y.C.; Chen Y.J.; Wang L.J.; Shi Y.J.; Chang L.S.; Quinacrine induces the apoptosis of human leukemia U937 cells through FOXP3\/miR-183\/&#x3B2;-TrCP\/SP1 axis-mediated BAX upregulation. Toxicol Appl Pharmacol 2017,334,35-46","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/glioma.glioma_37_18","volume":"1","author":"Zhang P.","year":"2018","unstructured":"Zhang P.; Li N.; Kiang K.M.; Zhu Z.; Leung G.W.; Cheng S.Y.; Leung G.K.;  Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and-resistant glioblastoma cellsGlioma 2018,1(5),105","journal-title":"Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and-resistant glioblastoma cellsGlioma"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2017.04.006","volume":"66","author":"Vitale I.","year":"2017","unstructured":"Vitale I.; Manic G.; De Maria R.; Kroemer G.; Galluzzi L.; DNA damage in stem cells. Mol Cell 2017,66(3),306-319","journal-title":"Mol Cell"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.trecan.2017.04.002","volume":"3","author":"Pons-Tostivint E.","year":"2017","unstructured":"Pons-Tostivint E.; Thibault B.; Guillermet-Guibert J.; Targeting PI3K signaling in combination cancer therapy. Trends Cancer 2017,3(6),454-469","journal-title":"Trends Cancer"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s13402-017-0347-3","volume":"40","author":"Das S.","year":"2017","unstructured":"Das S.; Nayak A.; Siddharth S.; Nayak D.; Narayan S.; Kundu C.N.; TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions. Cell Oncol (Dordr) 2017,40(6),593-607","journal-title":"Cell Oncol (Dordr)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ccr.2008.08.002","volume":"14","author":"Powers M.V.","year":"2008","unstructured":"Powers M.V.; Clarke P.A.; Workman P.; Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008,14(3),250-262","journal-title":"Cancer Cell"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.4161\/cc.8.23.10179","volume":"8","author":"Neznanov N.","year":"2009","unstructured":"Neznanov N.; Gorbachev A.V.; Neznanova L.; Komarov A.P.; Gurova K.V.; Gasparian A.V.; Banerjee A.K.; Almasan A.; Fairchild R.L.; Gudkov A.V.; Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications. Cell Cycle 2009,8(23),3960-3970","journal-title":"Cell Cycle"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/carcin\/bgs351","volume":"34","author":"Preet R.","year":"2013","unstructured":"Preet R.; Mohapatra P.; Das D.; Satapathy S.R.; Choudhuri T.; Wyatt M.D.; Kundu C.N.; Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis 2013,34(2),277-286","journal-title":"Carcinogenesis"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2019.105682","volume":"119","author":"Nayak D.","year":"2020","unstructured":"Nayak D.; Tripathi N.; Kathuria D.; Siddharth S.; Nayak A.; Bharatam P.V.; Kundu C.; Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway. Int J Biochem Cell Biol 2020,119","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/13895575113136660107","volume":"14","author":"Insan M.B.","year":"2014","unstructured":"Insan M.B.; Jaitak V.; New approaches to target cancer stem cells: Current scenario. Mini Rev Med Chem 2014,14(1),20-34","journal-title":"Mini Rev Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature21713","volume":"543","year":"2017","unstructured":"F.; Kurtova, A.V.; Harnoss, J.M.; Kljavin, N.; Hoeck, J.D.; Hung, J.; Anderson, J.E.; Storm, E.E.; Modrusan, Z.; Koeppen, H.; Dijkgraaf, G.J.; Piskol, R.; de Sauvage, F.J. A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. Nature de Sousa e Melo2017,543(7647),676-680","journal-title":"Nature"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10456-019-09669-x","volume":"22","author":"Krishnapriya S.","year":"2019","unstructured":"Krishnapriya S.; Sidhanth C.; Manasa P.; Sneha S.; Bindhya S.; Nagare R.P.; Ramachandran B.; Vishwanathan P.; Murhekar K.; Shirley S.; Ganesan T.S.; Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. Angiogenesis 2019,22(3),441-455","journal-title":"Angiogenesis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/jlb.66.6.876","volume":"66","author":"Roebuck K.A.","year":"1999","unstructured":"Roebuck K.A.; Finnegan A.; Regulation of intercellular adhesion\nmolecule-1 (CD54) gene expression. J Leukoc Biol, 1999,66(6),876-888","journal-title":"J Leukoc Biol,"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.4049\/jimmunol.1400135","volume":"192","author":"Ramos T.N.","year":"2014","unstructured":"Ramos T.N.; Bullard D.C.; Barnum S.R.; ICAM-1: Isoforms and phenotypes. J Immunol 2014,192(10),4469-4474","journal-title":"J Immunol"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/340296","volume":"2012","author":"Wai Wong C.","year":"2012","unstructured":"Wai Wong C.; Dye D.E.; Coombe D.R.; The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol 2012,2012","journal-title":"Int J Cell Biol"},{"key":"ref=77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122603","volume":"18","author":"Harada M.","year":"2017","unstructured":"Harada M.; Morimoto K.; Kondo T.; Hiramatsu R.; Okina Y.; Muko R.; Matsuda I.; Kataoka T.; Quinacrine inhibits ICAM-1 transcription by blocking DNA binding of the NF-&#x3BA;B subunit p65 and sensitizes human lung adenocarcinoma A549 cells to TNF-&#x3B1; and the Fas ligand. Int J Mol Sci 2017,18(12)","journal-title":"Int J Mol Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1158\/1078-0432.CCR-11-3237","volume":"18","author":"Kirschmann D.A.","year":"2012","unstructured":"Kirschmann D.A.; Seftor E.A.; Hardy K.M.; Seftor R.E.; Hendrix M.J.; Molecular pathways: Vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012,18(10),2726-2732","journal-title":"Clin Cancer Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"Carmeliet P.","year":"2011","unstructured":"Carmeliet P.; Jain R.K.; Molecular mechanisms and clinical applications of angiogenesis. Nature 2011,473(7347),298-307","journal-title":"Nature"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/biomedicines5020034","volume":"5","author":"Rajabi M.","year":"2017","unstructured":"Rajabi M.; Mousa S.A.; The role of angiogenesis in cancer treatment. Biomedicines 2017,5(2),34","journal-title":"Biomedicines"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1093\/carcin\/13.12.2321","volume":"13","author":"Popanda O.","year":"1992","unstructured":"Popanda O.; Thielmann H.W.; The function of DNA topoisomerases in UV-induced DNA excision repair: Studies with specific inhibitors in permeabilized human fibroblasts. Carcinogenesis 1992,13(12),2321-2328","journal-title":"Carcinogenesis"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/carcin\/14.11.2341","volume":"14","author":"Thielmann H.W.","year":"1993","unstructured":"Thielmann H.W.; Popanda O.; Gersbach H.; Gilberg F.; Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis 1993,14(11),2341-2351","journal-title":"Carcinogenesis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.2174\/092986712802002464","volume":"19","author":"Davar D.","year":"2012","unstructured":"Davar D.; Beumer J.H.; Hamieh L.; Tawbi H.; Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012,19(23),3907-3921","journal-title":"Curr Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biom2040524","volume":"2","author":"Ko H.L.","year":"2012","unstructured":"Ko H.L.; Ren E.C.; Functional aspects of PARP1 in DNA repair and transcription. Biomolecules 2012,2(4),524-548","journal-title":"Biomolecules"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"20600","DOI":"10.1038\/srep20600","volume":"6","author":"Nayak A.","year":"2016","unstructured":"Nayak A.; Satapathy S.R.; Das D.; Siddharth S.; Tripathi N.; Bharatam P.V.; Kundu C.; Nanoquinacrine induced apoptosis in cervical cancer stem cells through the inhibition of hedgehog-GLI1 cascade: Role of GLI-1. Sci Rep 2016,6,20600","journal-title":"Sci Rep"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/nrd2154","volume":"5","author":"Barker N.","year":"2006","unstructured":"Barker N.; Clevers H.; Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006,5(12),997-1014","journal-title":"Nat Rev Drug Discov"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00432-019-03055-2","volume":"146","author":"Sethy C.","year":"2020","unstructured":"Sethy C.; Goutam K.; Nayak D.; Pradhan R.; Molla S.; Chatterjee S.; Rout N.; Wyatt M.D.; Narayan S.; Kundu C.N.; Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse. J Cancer Res Clin Oncol 2020,146(1),245-259","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/183999","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.eurekaselect.com\/183999\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/eurekaselect.com\/article\/download\/183999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T14:42:29Z","timestamp":1641134549000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/183999\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200721123046","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}